The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Castagna
Antonella
A
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy.
Gianotti
Nicola
N
Galli
Laura
L
Danise
Anna
A
Hasson
Hamid
H
Boeri
Enzo
E
Hoetelmans
Richard
R
Nauwelaers
David
D
Lazzarin
Adriano
A
D000328:Adult; D018791:CD4 Lymphocyte Count; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D061466:Lopinavir; D008297:Male; D008826:Microbial Sensitivity Tests; D015999:Multivariate Analysis; D010641:Phenotype; D011744:Pyrimidinones / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir